Literature DB >> 1185045

Radioimmunoassays for Ig classes G, A, M, D, and E in spinal fluids: normal values of different age groups.

S T Nerenberg, R Prasad.   

Abstract

Radioimmunoassay procedures of sufficient sensitivity (IgG, 0.5 mug per 100 mul; IgA, 25.0 ng. per 100 mul; IgM, 10.0 ng. per 100 mul; IgD, 0.5 U. per 100 mul; and IgE, 1.0 U. per 100 mul) were developed detect and quantitate all 5 immunoglobulin classes in the cerebrospinal fluid on small aliquots (1 ml.) of unconcentrated cerebrospinal fluid. All 5 immunoglobulin classes were routinely detected in normal individuals for the first time, the levels varying with different age groups for IgG and A but not for the remaining immunoglobulin classes. Race and sex had no effect. Standardization of techniques and establishment of normal values for different age groups sets the stage for determination of immunoglobulin changes related to central nervous system disease.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1185045

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  13 in total

1.  Correlation between protein data in normal lumbar CSF and morphological findings of choroid plexus epithelium: a biochemical corroboration of barrier transport via tight junction pores.

Authors:  H Kluge; W Hartmann; B Mertins; V Wieczorek
Journal:  J Neurol       Date:  1986-08       Impact factor: 4.849

Review 2.  Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

Review 3.  Immunotherapy for tauopathies.

Authors:  Jiaping Gu; Einar M Sigurdsson
Journal:  J Mol Neurosci       Date:  2011-07-08       Impact factor: 3.444

4.  Study of fluorescent treponemal antibody test on cerebrospinal fluid using monospecific anti-immunoglobulin conjugates IgG, IgM, and IgA.

Authors:  G Leclerc; M Giroux; A Birry; S Kasatiya
Journal:  Br J Vener Dis       Date:  1978-10

Review 5.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

6.  An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.

Authors:  Einar M Sigurdsson; Elin Knudsen; Ayodeji Asuni; Cheryl Fitzer-Attas; Daniel Sage; David Quartermain; Fernando Goni; Blas Frangione; Thomas Wisniewski
Journal:  J Neurosci       Date:  2004-07-14       Impact factor: 6.167

7.  IgE levels in intestinal juice.

Authors:  D Belut; D A Moneret-Vautrin; J P Nicolas; J P Grilliat
Journal:  Dig Dis Sci       Date:  1980-05       Impact factor: 3.199

Review 8.  Tau-based treatment strategies in neurodegenerative diseases.

Authors:  Anja Schneider; Eckhard Mandelkow
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

9.  Intramembranous fragment of amyloid-beta: A potential immunogen for Alzheimer's disease immunotherapy.

Authors:  Songjiang Zhang; Lixiang Wu; Fayi Liu; Bosheng Huang; Dong Huang; Lijuan Yang; Zhihong Peng
Journal:  Neurochem Res       Date:  2009-04-04       Impact factor: 3.996

10.  Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives.

Authors:  Stéphanie G Trouche; Ayodeji Asuni; Sylvie Rouland; Thomas Wisniewski; Blas Frangione; Jean-Michel Verdier; Einar M Sigurdsson; Nadine Mestre-Francés
Journal:  Vaccine       Date:  2008-12-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.